Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets.

Cooley, Rachel; Kara, Neesha; Hui, Ning Sze; Tart, Jonathan; Roustan, Chloë; George, Roger; Hancock, David C; Binkowski, Brock F; Wood, Keith V; Ismail, Mohamed; Downward, Julian

Cooley, Rachel; Kara, Neesha; Hui, Ning Sze; Tart, Jonathan; Roustan, Chloë; George, Roger; Hancock, David C; Binkowski, Brock F; Wood, Keith V; Ismail, Mohamed; Downward, Julian.

Affiliation

Cooley R; Francis Crick Institute, London, UK.
Kara N; Francis Crick Institute, London, UK.
Hui NS; Francis Crick Institute, London, UK.
Tart J; AstraZeneca, Cambridge, UK.
Roustan C; Francis Crick Institute, London, UK.
George R; Francis Crick Institute, London, UK.
Hancock DC; Francis Crick Institute, London, UK.
Binkowski BF; Promega, Madison, Wisconsin, USA.
Wood KV; Promega, Madison, Wisconsin, USA.
Ismail M; Francis Crick Institute, London, UK.
Downward J; Francis Crick Institute, London, UK.

Wellcome Open Res ; 5: 20, 2020.

Article de En | MEDLINE | ID: mdl-32587898

Mots clés

KRAS; PI3K; RAF; luciferase; protein-protein interaction; screening

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Diagnostic_studies / Screening_studies Langue: En Journal: Wellcome Open Res Année: 2020 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google